• Home
  • HCN Trends
  • Contact Us

Search Articles

Cardiology Covid-19 Dermatology Endocrinology General Interest Hematology Infectious Disease Neurology Oncology Pediatrics Psychiatry Pulmonology Rheumatology Surgery Uncategorized
acetaminophen actemra adverse events anemia antibody anxiety aspirin azithromycin bipolar disorder bleeding blog brain tumor breast cancer burnout Cancer capecitabine capmatinib cervical cancer chloroquine chronic pain clinical trials cll cloroquine CME compensation core-binding factor coronary artery disease coronavirus cost covid-19 cvd death diagnosis disease doctors dosing drug drug interactions efficacy erlotinib exercise FDA/regulation fever filters fish oil glioblastoma green tea guidelines hemophilia hiv hospital hydroxychloroquine ibrutinib ibuprofen immunity induction chemotherapy infectious disease influenza ipilimumab irinotecan iron-deficiency anemia isn letrozole leukemia Lung cancer malaria malpractice mask Masks mbc MDS medical cannabis medical school Medicine mesothelioma metastatic colorectal cancer methotrexate Myelodysplastic Syndromes myeloid leukemia nivolumab nsclc nursing oil olaparib osimertinib outcomes pandemic patient safety patients pd pediatrics perjeta physicians podcast practice practice management prevention primer procedure prostate cancer radiation recovery remdesivir research/studies respirators respiratory retevmo risk rucaparib sars SARS-CoV-2 infection SCLC selinexor selpercatinib side effects sorafenib stroke Survival/Mortality symptoms syndrome tazemetostat telemedicine testing therapeutics therapy thrombosis thyroid cancer time tnbc tocilizumab trastuzumab trauma treatment tweet vaccine venclexta venetoclax walking wound xpovio

March 30, 2021 | Oncology
Metastatic CRC OS | mRNA Vaccine Response | RCTs in Precision Oncology

HMP Communications Anlotinib Prolongs OS in RAS, KRAS, BRAF-Wildtype Metastatic CRC

According to research presented at the virtual ASCO GI Cancers Symposium from the phase 3 ALTER0703 trial, anlotinib was beneficial in Chinese patients with refractory metastatic colorectal cancer (CRC), with particular overall survival (OS) improvement – the primary endpoint – among patients with RAS/KRAS/BRAF-wildtype.

Everyday Health Cancer Patients Respond Poorly to First COVID mRNA Vax Dose

The data, concluded in a report posted to the preprint server medRxiv, support prioritization of cancer patients for an early (21-day) second dose of the BNT162b2 vaccine, as barely one-quarter of patients with cancer obtained protection (28% immune efficacy rate, including 13% in patients with blood cancers) against COVID-19 after one dose of the Pfizer/BioNTech […]

American Medical Association Evolution of the Randomized Clinical Trial in the Era of Precision Oncology

In this Original Investigation from JAMA Oncology, the authors seek to discover the characteristics that define modern randomized clinical trials (RCTs) in oncology and whether they differ from characteristics of RCTs from the preceding decades, as concerns have emerged regarding the use of putative surrogate end points, such as progression-free survival (PFS), and marginal effect […]
  • © Healthcare Communications Network
  • Privacy Policy